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Abstract   
Introduction Stroke rate and mortality are greater in people with end-stage renal 
disease (ESRD) than those without. We examined discrepancies in stroke-care in 
ESRD patients and its influence on mortality. 
 Methods A national record-linkage cohort study of hospitalised stroke from 2005-
2013.   Presentation, measures of care quality (admission to stroke unit, swallow 
assessment, anti-thrombotic or thrombolysis use) and outcomes were compared in 
those with and without ESRD after propensity score matching (PSM). We examined 
the effect being admitted to a stroke unit on survival using Kaplan-Meier and Cox 
survival analyses.   
Results 8,757 people with ESRD and 61,367 people with stroke were identified.  
486 ESRD patients experienced stroke over 34,551.9 years follow-up; incidence 
rates 25.3 (dialysis) and 4.5 (kidney transplant)/ 1000 patient-years.  Following PSM, 
dialysis patients were less likely to be functionally independent (61.4 vs 77.7%, 
p<0.0001) before stroke, less frequently admitted to stroke units (64.6 vs 79.6%, 
p<0.001) or receive aspirin (75.3 vs 83.2%, p=0.01) than non-ESRD stroke patients. 
There were no significant differences in management of kidney transplant patients.  
Stroke with ESRD associated with higher death rate during admission: dialysis 22.9 
vs 14.4%, p=0.002; transplant: 19.6 vs 9.3%, p=0.034. Managing ESRD patients on 
a stroke unit associated with lower risk of death at follow-up (HR 0.68, 95% CI 0.55-
0.84).   
Conclusions Stroke incidence is high in ESRD. People on dialysis are functionally 
more dependent before stroke and less frequently receive optimal stroke care. 
Following stroke, death is more likely in ESRD patients. Acute stroke unit care may 
associate with lower mortality.  
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Introduction 
Declining kidney function is associated with increased cardiovascular risk1 and the 
presence of chronic kidney disease (CKD) is incorporated into risk prediction 
algorithms used to guide preventative treatments for cardiovascular disease2,3. Risk 
is greatest in end-stage renal disease (ESRD), at approximately 5 to 20 times that of 
the age-matched controlled general population4,5, and treatments such as dialysis or 
immunosuppression for kidney transplantation may further increase risk6,7. Risk of 
stroke is reported to be 10-fold more common in ESRD8,9 yet case mix presentation, 
management and outcomes of stroke in individuals with ESRD remains poorly 
understood.  
In ESRD provision of evidence-based management of cardiovascular disease and 
stroke prevention is hindered10–12 by limited evidence of benefit with interventions 
such as statins13 or anticoagulation14 and advanced CKD is a common exclusion 
criterion in trials targeting cardiovascular risk15. People with ESRD are typically 
admitted to renal units when hospitalised for intercurrent illness10,16. This could 
impact on access to stroke unit care and treatments shown to improve stroke 
outcomes17.   
We assessed incidence of stroke in ESRD and if the presence of ESRD influenced 
presentation, management and outcome of stroke by merging data from the Scottish 
Renal Registry and Scottish Stroke Care Audit. We hypothesised key care quality 
indicators in stroke would be less commonly achieved in those with ESRD compared 
those without. 
 
 
Methods 
We performed a national data linkage study using data within the Scottish Renal 
Registry, Scottish Stroke Care Audit, Scottish Morbidity Records and the National 
Records of Scotland. We used propensity score matching (PSM) and assessed case 
mix presentation, measures of care quality and outcome following stroke in people 
with and without ESRD. 
Datasets 
The Scottish Renal Registry (SRR) is a nation-wide dataset, contributed to by all 
renal units in Scotland18,19. All patients receiving renal replacement therapy (RRT) for 
ESRD are included. The SRR records patient demographics, renal replacement 
modality, clinical measurements, laboratory results and cause of death.  
The Scottish Stroke Care Audit (SSCA) monitors performance of stroke care against 
guideline derived standards throughout Scotland. Data held by the SSCA includes all 
cases of stroke and transient ischaemic attack admitted to hospital. Ascertainment of 
stroke cases in the SSCA is carried out by trained audit co-ordinators supported by 
stroke clinicians. Data are collected on demographics, case mix at presentation, 
stroke classification, use of brain imaging, antithrombotic medication, stoke unit care 
and discharge outcomes. This dataset has provided coverage of all hospitals 
managing acute stroke since 2005.  
The Scottish Morbidity Records 01 (SMR01) collects data on all surgical and medical 
hospital admissions since 1968. Since 1989 SMR01 has been used to plan hospital 
finances to ensure high completion rate.  
The National Records of Scotland is a department of Scottish Government, 
responsible for registration of life events including deaths.  
All four datasets were linked, over the period 1st January 2005 to 31st December 
2013. We included only adults (≥16 years at stroke) in our analyses. Supplementary 
figures 1 and 2 demonstrate the construction of linked datasets for analysis.   
Definitions 
Stroke 
Only cases of confirmed stroke as final diagnosis were included. The SMR01 was 
interrogated for ICD codes for stroke I60, I61, I62.9, I63 and I64. All stroke 
diagnoses were ordered by date of stroke from 01 January 2005 and first recorded 
stroke date, with source of diagnosis recorded. In cases where SMR01 and SSCA 
diagnoses overlap, the SSCA was used as the source.  
End-Stage Renal Disease 
All patients commencing RRT for ESRD in Scotland are recorded within the SRR. 
ESRD is a diagnosis determined by the clinician initiating RRT, or continued use of 
RRT for >90 days for acute kidney injury without renal recovery.  
Modality of renal replacement therapy 
We considered three groups of ESRD patients; (1) all people with ESRD regardless 
of RRT modality, (2) people receiving dialysis (either haemodialysis (HD) or 
peritoneal dialysis (PD) at the start of study, or who began HD or PD as their first 
RRT modality during the study) and (3) people with a kidney transplant: either at 
commencement of the study or who were transplanted during the study de novo or 
following a period of dialysis.  
 
Baseline Characteristics 
The SMR01 was interrogated from 01 January 1981 until 31 December 2013 for 
presence of ICD-10 codes relating to atrial fibrillation/flutter (I48), ischemic heart 
disease (I21, 24, 24.8, I24.9, I25, I25.1, I25.2, I25.5 and I25.8), diabetes mellitus 
(E10 and E11), and hypertension (I10 and I15). To prevent overlap of diagnoses, 
ICD codes for stroke (above) were pulled from 1981 until date of first stroke in 
people who experienced stroke, or until 31.12.2013 in people who did not.   
Using Scottish Government urban-rural and socioeconomic classifications based on 
patient postcode we subdivided patients into most or least deprived and urban or 
rural as described elsewhere20. We used postcode at commencing RRT in people on 
RRT or at stroke for the non-ESRD stroke population.  
SSCA Auditable Standards  
The SSCA annually report standards of stroke care compared to audited targets. 
Specifically, the percentage with access to a stroke unit within 1 day of admission, 
brain imaging within 24 hours of admission, swallow screen on day of admission, 
aspirin within 1 day of admission (if index stroke is ischaemic) and thrombolysis 
within one hour of arrival to hospital. We present two forms of data regarding these 
standards. Firstly, percentage of cases who received the following at any point 
during their admission: stroke unit care, brain imaging, swallow screen, aspirin or 
thrombolysis. Secondly, we re-analysed using date and time of admission to hospital 
and date and time of each care standard to determine time-specific outcomes as per 
the SSCA standards.   
 
Mortality 
Using the national death records we determined vitality status until 25.09.2015 for all 
persons. Death during stroke admission and vitality status at end of follow-up are 
presented. When exploring the impact of stroke care on mortality we omitted cases 
of stroke diagnosed only at death and analysed both ESRD and non-ESRD 
populations based on source of initial diagnosis – SSCA or SMR01. Causes of death 
for all patients are presented as per ICD-10 rules in supplementary material (tables 
s6-s8).  
Statistical Analyses 
Data cleaning and analyses were performed using SAS, v9.4 (SAS Institute Inc, 
Cary, NC, USA).  Graphs were produced using Stata v14.1 (Statacorp, College 
Station, TX, USA).  
Incidence rates are expressed per 1000-patient years and calculated using number 
of stroke events divided by follow-up time. Follow-up time is calculated using date of 
study entry (01.01.2005) or start of RRT for ESRD until date of stroke, death, change 
of renal replacement modality or end of study.  
We compared patient demographics split by source of stroke diagnosis; SSCA vs 
SMR01 and stroke vs no stroke. Demographic values are presented as means 
(standard deviation, SD) or medians (inter-quartile range, IQR) and comparison 
between groups is made using t-test, Mann-Whitney U or Chi-square as appropriate. 
To account for differences in cohort size, we compare pre- and post- matching 
demographics using standardised differences.  
Propensity score matching (PSM) – People with ESRD and stroke are more likely 
to have co-morbidities than people without. To reduce potential for confounding we 
performed PSM to all ESRD patients, then individually to each of those on dialysis 
and with a renal transplant. Matching was based on factors predictive of stroke or 
outcome. Specifically we matched on age, sex, deprivation and rurality status and 
past medical history of stroke, ischaemic heart disease, hypertension, diabetes and 
atrial fibrillation. We matched using ‘nearest neighbour matching’, at a ratio of 5:1. 
Data are tabulated for each cohort; all ESRD, dialysis and kidney transplant. Data 
are presented before and after PSM in each case, with comparison between groups 
using Mann-Whitney U or Chi-square as appropriate. As our primary aim was to 
directly compare cohorts missing data were not imputed, but rather are presented 
within each table.  PSM  was performed using the computing environment R, MatchIt 
package21.  
Survival analyses were performed using the Kaplan-Meier estimator and Cox 
proportional hazard model. We assessed differences between survival probabilities 
following stroke in dialysis, kidney transplant and non-ESRD stroke populations. 
Finally, to explore effects of care on outcome, we used admission to a stroke unit as 
a surrogate for optimal stroke care in ESRD (adjusted for age, sex, use of dialysis, 
prior diabetes, ischaemic heart disease, hypertension and atrial fibrillation) to 
examine its impact on death at follow-up.   
Ethical Approval 
The datasets used work within the “NHS Code of Practice on Protecting Patient 
Confidentiality” incorporating requirements of statute and common law including the 
Data Protection, Human Rights and the Adults with Incapacity (Scotland) 
Acts. Access and use of data was approved following NSS proportionate governance 
review by the Privacy Advisory Committee of ISD, NHS Scotland Reference 55/14. 
 
Results 
ESRD Stroke Incidence Rate and Stroke Record Source 
There were 8757 people aged 16 or older in the Scottish Renal Registry from 01 
January 2005 to 31 December 2013. 6749 were receiving dialysis at study entry and 
3699 had a kidney transplant at entry or were transplanted during follow-up. 486 
(5.5%) people experienced stroke during a period of 34,551.9 years of follow-up. The 
stroke incidence rate per 1000 patient-years for all people with ESRD was 14.1, for 
people on dialysis it was 25.3 (26.7 for HD and 17.3 for PD), and for people with a 
kidney transplant it was 4.5.  
Of the first recorded stroke episode during the study period, 230 (47.3%) were 
recorded in the SSCA, 219 (45.1%) in the SMR01 and 37 (7.6%) as primary cause of 
death, but not recorded prior to death.  No significant differences existed in baseline 
demographics between people with ESRD and stroke in the SMR01 database 
compared to the SSCA database, table 1   
Demographics in ESRD: Stroke vs No Stroke  
In all people with ESRD, there were differences between those who experienced 
stroke and those who did not (table 2). People with stroke were older at commencing 
RRT, more likely to have atrial fibrillation, prior stroke and diabetes. In the dialysis 
group prior ischaemic heart disease did not associate with stroke, whereas higher 
serum phosphate did. In the transplant group, the inverse was true; prior ischaemic 
heart disease and lower serum phosphate associated with stroke. Further details are 
outlined in supplementary tables s1 and s2.  
Demographics: SSCA Stroke in ESRD vs SSCA Stroke in Non-ESRD 
Population  
We identified 61,367 people registered in the SSCA with stroke during our study 
period. 280 (0.5%) people in the SSCA dataset were on RRT for ESRD. Compared 
to the background population, people with ESRD developed stroke at a younger age, 
had a greater prevalence of prior ischaemic heart disease, hypertension and 
diabetes, table 3. Similar was found in people on dialysis, table 4. In the renal 
transplant population, there were differences in age, sex, hypertension and diabetes 
status, table 5. PSM removed all demographic differences, tables 3-5.   
Output following Propensity Score Matching - Case Mix 
People with ESRD were less likely to be independent in activities of daily living 
(63.8% vs 78.6%, p<0.0001) and less likely to be living alone (22.9% vs 30.8%, 
p=0.025) prior to admission. Similar was found in people on dialysis but there were 
no significant differences between people with a kidney transplant and the non-
ESRD stroke population, tables 3-5.  
Output following Propensity Score Matching - Admission Source 
People with ESRD and people treated with dialysis were more likely to present via 
an acute hospital rather than home (7.5% vs 2.2%, p<0.0001 and 9.4% vs 2.4%, 
p<0.0001 respectively).  Transplant recipients were more likely to be admitted from 
home (96.4% vs 91.1%, p=0.032), compared the non-ESRD stroke population, 
tables 3-5.  
Output following Propensity Score Matching – Stroke Care & Audit Standards 
People with ESRD and people treated with dialysis were less likely to be managed 
on an acute stroke unit during their admission (67.4% vs 79.6%, p<0.001 and 64.6% 
vs 79.6%, P<0.001 respectively) and less likely to receive aspirin (74.8% vs 83.6%, 
p=0.002 and 75.3% vs 83.2%, p=0.01 respectively). There were no differences in 
management of transplant recipients compared to the non-ESRD stroke population, 
tables 3-5.  
People on dialysis were less likely to be admitted to a stroke unit on day 0 or 1 (43.5 
vs 62.6%, p=0.005), less likely to have a swallow screen within the first 24 hours 
(66.4% vs 74.1%, p=0.017) and less likely to receive thrombolysis within 60 minutes 
(1.5 vs 3.9%, p=0.016).  These measures did not differ in kidney transplant 
recipients, supplementary tables 3-5.  
Propensity Score Matching - Discharge Destination 
People with ESRD and people on dialysis were more likely to remain in an NHS 
inpatient bed (15.1% vs 4.7%, p<0.0001 and 17.0% vs 4.8%, p<0.0001 respectively) 
and less likely to be discharged to home or sheltered accommodation (54.5% vs 
70.2%, p<0.0001 and 50.7% vs 68.6%, p<0.0001). This association was not present 
in people with a kidney transplant. In both dialysis and kidney transplant patients in-
hospital mortality was almost double the rate demonstrated in people without ESRD 
(dialysis: 22.9 vs 14.4%, p=0.002; transplant: 19.6 vs 9.3%, p=0.034). 
 
 
 
ESRD Mortality following Stroke 
At end of follow-up 4621 (52.8%) of people with ESRD had died. Death was more 
likely in people who were older, with high cardiovascular comorbidity burden and 
experienced stroke during follow-up. Further demographics are presented in table 6.  
229 (81.8%) of the 280 people with ESRD who experienced stroke had died, 
compared to 33169 (54.3%) of 61,087 in the general stroke population.  The higher 
mortality rate remained after PSM, (85.7 vs 52.9% for dialysis, p<0.0001 and 66.1 vs 
41.8% for transplant, p=0.001), tables 4 & 5.  
Median survival [IQR] following stroke was 0.8 [2.1] years in people on dialysis, 2.5 
[3.8] years in people with a kidney transplant and 3.1 [4.4] years in the non-ESRD 
stroke population, p <0.0001, figure 1. 
When assessing all stroke episodes in both ESRD and non-ESRD populations, there 
is demonstrably lower survival in people with ESRD than those without. Furthermore, 
presence of first recorded stroke episode during follow-up within the SMR01 is 
associated with lower survival than those recorded within the SSCA, figure 2. 
In people with ESRD only, 157 (35.0%) of first recorded strokes were admitted to a 
stroke unit. At follow-up, mortality was lower in those admitted to a stroke unit 
(82.8% vs 91.1%, p=0.014). On multivariable analysis, admission to a stroke unit 
was associated with lower risk of death, HR [95% CI] 0.68 [0.55-0.84], p<0.001, 
figure 3 and supplementary table s6. 
  
Discussion 
In this population based record linkage cohort study we demonstrated that incidence 
of stroke in ESRD is high and higher in people receiving dialysis compared to kidney 
transplant recipients. We found people with ESRD who experience stroke are more 
functionally dependent at presentation, there are differences in delivery of stroke 
care to people with ESRD and in-hospital death from stroke was higher. These 
findings suggest that provision of stroke care for people with ESRD needs urgent 
review. 
The stroke rate of 25.3 and 4.5 per 1000 patient-years in people on dialysis or 
transplant recipients respectively, is in keeping with previous published 
reports8,20,22,23. During the same time period, the crude incidence rate for 
cerebrovascular disease in Scotland was 2.4/1000 patient-years24, demonstrating a 
10 fold increase in stroke incidence in people receiving dialysis. In real-world terms, 
in our renal unit with prevalent population of approximately 650 dialysis recipients 
this equates to one stroke every 22 days or, nationally, one stroke per week.   
Stroke incidence and Presentation 
People on dialysis were functionally more dependent at presentation than their 
matched non-ESRD stroke population cohort. Functional dependence is common in 
ESRD25 and an independent predictor of mortality26. Patients receiving dialysis were 
more likely to be admitted from an acute hospital than home. There are possible 
explanations for this. Primarily there is an increased likelihood of hospitalisation in 
ESRD27 but also a temporal relationship between dialysis itself and stroke28. In one 
single-centre study, 39.5% of infarcts and 34.7% haemorrhages occur during or 
within 30 minutes of completing dialysis.  It is likely that such strokes would initially 
be referred to nephrology.   
Inequalities in Care 
As well as being less likely to be managed in acute stroke units, people with ESRD 
treated with dialysis were less likely to undergo a swallow test within the first 24 
hours, less likely to receive aspirin on arrival to hospital, and less likely to receive 
prompt thrombolytic therapy. Interestingly, this pattern of care was not seen in renal 
transplant recipients. Differences in care following myocardial infarction in ESRD 
have been previously demonstrated but have been attributed to lack of accurate 
diagnosis at first assessment due to higher rates of atypical symptoms and ECG 
changes12. In our cohort presenting symptoms were similar between groups so we 
feel delayed recognition of stroke does not explain the differences. It is possible that 
practical considerations surrounding need for dialysis makes stroke unit care 
impractical or unattractive. In a survey of nephrologists it was felt that adverse 
effects of dialysis schedules, coupled with lack of stroke unit care may negatively 
impact on recovery and requires future attention16. An alternate explanation is that 
specialist stroke units may feel uncomfortable caring for dialysis patients and elect 
not to transfer care.  
Only 280 of 486 strokes that occurred in people with ESRD were included in the 
SSCA dataset. It is thought that the SSCA most accurately represents the number of 
strokes occurring in Scotland29. It is acknowledged that omission of strokes from the 
SSCA can occur if the patient was in hospital at the time of stroke or was not 
referred promptly to stroke services. Such a high number of strokes not recorded in 
the SSCA was unexpected and suggests substantial inequality in access to gold 
standard stroke care for people with ESRD. A recent paper addressing selection bias 
following stroke demonstrated consistent improvement up to one year following 
stroke from use of stroke units17. We explored this discrepancy, examining effects of 
admission to a stroke unit as a marker of optimal stroke care. People with ESRD 
admitted to a stroke unit had a significantly lower mortality rate at follow-up than 
those who were not. Importantly, it must be acknowledged this may be in part related 
to selection bias at the time of stroke; those more severely affected at presentation 
may not be referred onward 
Discrepancies in mortality 
Mortality following stroke is declining in general population studies30 but we found 
striking differences in mortality rates - both during stroke admission and on longer 
follow-up.  This extended to people with ESRD and a kidney transplant who were 
twice as likely to die on their initial admission and had higher mortality rates at follow-
up.  As our matching process controlled for hypertension, diabetes and ischaemic 
heart disease, an accrued risk specific to CKD not reversed by transplantation 
seems a likely explanation.  This is an important finding as transplant recipients with 
normal range serum creatinine could be overlooked as lower risk. Unfortunately, 
creatinine values are not available in our non-ESRD population data.  
Finally, we detected significant differences in survival based on diagnosis source; 
higher survival in people diagnosed via SSCA compared to people in the SMR01 
and higher survival in those admitted to a stroke unit. These findings support the 
conclusion that specialist stroke care associates with a lower mortality rate in people 
with ESRD. Whilst this may relate to ‘therapeutic nihilism’ in cases of more severe 
stroke we cannot provide data to support this. Therefore, serious consideration must 
be paid to the merits of managing stroke on a renal ward for reasons of dialysis 
practicalities alone. 
Strengths and Limitations 
Linkage of national datasets provides a large population with unique results 
demonstrating issues relevant to patient care. Our main strengths include large 
numbers of patients in both ESRD and stroke populations. Scotland is broadly 
representative of both European nephrology and stroke care in terms of patient 
demographics and outcomes for both conditions31,32. Furthermore, the granularity of 
data allows description of the stroke pathway from presentation to discharge, use of 
death records allows a follow-up period and since 2005 both the SRR and SSCA are 
all-inclusive datasets. We supported complete capture by accessing the SMR01 
dataset. Despite these strengths, we acknowledge limitations. Firstly, all data are 
retrospective and therefore we cannot prove causation, rather describe associations. 
As it is not feasible to study the primary outcome of our study - impact of ESRD on 
outcomes following stroke - in a randomised fashion we have addressed the 
retrospective nature of the data by performing PSM. Second, missing data limits 
ability to fully exclude other factors influencing outcome. For instance, we lack 
markers of stroke severity (e.g. National Institutes of Health Stroke Scale) as this is 
only recorded where thrombolysis is used. Finally, discrepancies in survival following 
stroke split by diagnosis source warrants attention. Selection bias could result in 
frailer, more unwell patients bypassing the stroke unit (and omission from the SSCA) 
following deterioration on dialysis. Non-specialist input may result in misdiagnosis. 
However, internal validation of SMR01 coding confirms approximately 90% accuracy 
rate33 making this unlikely.   
Conclusions 
Stroke is common in individuals with ESRD with poor outcomes. People on dialysis 
are functionally more dependent at presentation and less likely to be managed on a 
stroke unit. People with a renal transplant are similar at presentation and provided 
with equivalent care to the general population, but retain a significantly higher 
mortality rate. ESRD should not exclude individuals from ideal care following stroke 
and efforts should be made to deliver such care to all.  
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Figure Legends 
Figure 1 Kaplan Meier estimator survival curves demonstrating time to death 
following stroke in matched non-ESRD population, transplant recipients and dialysis 
patients, Log-Rank test p<0.0001. Abbreviations: ESRD, end-stage renal disease  
Figure 2 Kaplan Meier survival curves demonstrating time to death following stroke 
in both ESRD and non-ESRD populations, split by source of stroke diagnosis: Non-
ESRD SSCA, Non-ESRD SMR01, ESRD population SSCA and ESRD population 
SMR01, Log-Rank test p<0.0001. Abbreviations: ESRD, end-stage renal disease; 
SMR01, Scottish Morbidity Records 01; SSCA, Scottish Stroke Care Audit  
Figure 3 Kaplan Meier survival curves demonstrating time to death following stroke 
in patients with end-stage renal disease, the effect of admission to an acute stroke 
unit, Log-Rank test p<0.0001. Abbreviations: ASU. Acute Stroke Unit 
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stroke.  
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Supplementary Figure 1 Flow diagram demonstrating construction of the dataset to 
calculate stroke incidence in patients with ESRD, 2005 -2013.   
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compare presentation, management and outcomes following stroke and propensity 
score matching. 
Supplementary Figure 3 Kaplan Meier survival estimator demonstrating time to 
death following stroke, split by matched non-ESRD stroke population, kidney 
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Rank test, p<0.0001.  
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SSCA Stroke SMR01 Stroke p-value 
n 230 219 
 Age at Stroke, Median years (IQR) 71 (13) 71 (17) 0.406 
Sex, n (%) 
          Female (%) 111 (48.3) 93 (42.5) 
        Male (%) 119 (51.7) 126 (57.5) 0.220 
Primary Renal Diagnosis group, n (%) 
          Glomerulonephritis 36 (15.7) 31 (14.2) 0.692 
       Interstitial disease 48 (20.9) 46 (21.0) 1.000 
       Multisystem 53 (23.0) 46 (21.0) 0.649 
       Diabetic nephropathy 57 (24.8) 60 (27.4) 0.591 
       Other 36 (15.7) 36 (16.4) 0.898 
Urban-Rural, n (%) 
          Rural 34 (14.8) 35 (16.0) 
        Urban 196 (85.2) 184 (84.0) 0.794 
SIMD, n (%) 
          Least Deprived  171 (74.4) 154 (70.3) 
        Most Deprived 59 (25.7) 65 (29.7) 0.344 
Era of Stroke. n (%)    
       2005-6 54 (23.5) 88 (40.2)  
       2007-8 50 (21.7) 44 (20.1)  
       2009-10 43 (18.7) 48 (21.9)  
       2011-13 83 (36.1) 39 (17.8) <0.001 
Past Medical History, n (%) 
          Atrial Fibrillation 21 (9.1) 30 (13.7) 0.139 
       Ischaemic heart disease 81 (35.2) 86 (39.3) 0.381 
       Prior Stroke  20 (8.7) 24 (11.0) 0.432 
       Diabetes 90 (39.1) 90 (41.1) 0.701 
       Hypercholesterolaemia  41 (17.8) 34 (15.5) 0.530 
       Obesity  15 (6.5) 14 (6.4) 1.000 
       HBP  171 (74.5) 164 (74.9) 0.914 
Clinical Variables, Median (IQR) 
          Systolic BP, mmHg 146.0 (30.0) 141.0 (28.8) 0.475 
       Diastolic BP, mmHg 69.8 (22.0) 68.5 (17.5) 0.894 
       Weight, kg 68.4 (28.0) 71.8 (23.1) 0.213 
Laboratory Variables, Median (IQR) 
          Haemoglobin, g/L 11.5 (1.8) 11.4 (1.7) 0.825 
       Albumin, mmol/L 36.0 (7.0) 37.8 (6.0) 0.171 
       Serum Phosphate, mmol/L 1.45 (0.61) 1.48 (0.62) 0.449 
       Adjusted Calcium, mmol/L 2.33 (0.2) 2.35 (0.2) 0.220 
       ESA Use 
   Death at follow-up 191 (83.0) 205 (93.6) <0.001 
 
Table 1 Baseline demographics of all end-stage renal disease patients with stroke, split by source of 
diagnosis. SSCA, Scottish Stroke Care Audit; SMR01, Scottish Morbidity Records 01; IQR, 
Interquartile Range; SIMD, Scottish Index of Multiple Deprivation; ESA, erythropoietin-stimulating 
agent.  
  
 
No Stroke Stroke p-value 
n 8271 486 
 Age at first RRT, median years (IQR) 56.4 (30.6) 66.3 (19.3) <0.0001 
Sex (%)       
       Female 3494 (41.7) 221 (45.5) 
        Male  4893 (58.3) 265 (54.5) 0.098 
Primary Renal Diagnosis group (%)       
       Glomuleronephritis 1532 (18.5) 70 (14.4) 0.022 
       Interstitial disease 2205 (26.7) 102 (21.0) 0.006 
       Multisystem 1680 (20.3) 114 (23.5) 0.105 
       Diabetic nephropathy 1463 (17.7) 122 (25.1) <0.0001 
       Other 1379 (16.7) 78 (16.1) 0.754 
       Missing 12 (0.1) 0  
Urban-Rural (%)       
       Rural 1380 (16.7) 75 (15.4) 
        Urban 6891 (83.3) 411 (84.6) 0.491 
SIMD (%)       
       Least Deprived  6129 (74.1) 356 (73.3) 
        Most Deprived  2142 (25.9) 130 (26.8) 0.670 
Past Medical History (%)       
       Atrial Fibrillation  502 (6.1) 52 (10.7) <0.001 
       Ischaemic Heart disease 2519 (30.5) 176 (36.2) 0.012 
       Stroke 272 (3.3) 48 (9.9) <0.001 
       Diabetes 2468 (29.8) 193 (39.7) <0.001 
       Hypercholesterolaemia  1053 (12.7) 80 (16.5) 0.022 
       Obesity  464 (5.6) 31 (6.4) 0.480 
       HBP  5894 (71.3) 361 (74.3) 0.233 
Clinical Variables. Median (IQR)       
       Systolic BP, mmHg 138 (29.0) 142 (30.0) <0.001 
       Diastolic BP, mmHg 72 (18.0) 69 (20.0) 0.077 
       Weight, kg  72.7 (23.0) 70.3 (25.6) 0.008 
Laboratory Variables       
       Haemoglobin, g/L 11.7 (1.9) 11.45 (1.5) <0.001 
       Albumin, mmol/L 38.0 (7.0) 37.0 (7.0) <0.001 
       Serum Phosphate, mmol/L 1.35 (0.6) 1.46 (0.6) <0.001 
       Adjusted Calcium, mmol/L 2.37 (0.2) 2.35 (0.2) 0.004 
       ESA Use 4873 (58.9) 268 (55.1) 0.107 
Death at follow-up 4188 (50.6) 433 (89.1) <0.001 
 
Table 2 Baseline demographics of all end-stage renal disease patients, no stoke vs stroke. IQR, 
Interquartile Range; SIMD, Scottish Index of Multiple Deprivation; RRT, Renal Replacement Therapy; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; ESA, erythropoietin-stimulating agent.  
  
 Variable 
  
Non-ESRD Population 
(61,087) 
 
ESRD Population 
(280) 
 
Standardised 
difference†/ 
p-value 
 
 
Propensity-Matched  
Non-ESRD Population 
(1,395) 
 
Propensity-Matched 
Renal Population  
(279) 
 
 
Standardised 
difference†/ 
p-value 
 
Patient Demographics 
    
 
   
       Age at stroke, median years [IQR]  76 [17.0] 71 [16.0] -0.48  70 [17.0] 70 [17.0] -0.01 
       Female, n [%]  31368 [51.4] 140 [50.0] -0.03  713 [51.1] 139 [49.8] -0.03 
       Rural, n [%]  10015 [16.4] 41 [14.6] -0.05  187 [13.4] 41 [14.7] 0.04 
       Deprived, n [%]  29709 [48.6] 138 [49.3] 0.01  713 [51.1] 138 [49.5] -0.03 
       Prior AF, n [%]  5019 [8.2] 26 [9.3] 0.03  102 [7.3] 26 [9.3] 0.07 
       Prior CeVD, n [%]  3555 [5.8] 27 [9.6] 0.14  111 [8.0] 26 [9.3] 0.05 
       Prior IHD, n [%]  12025 [19.7] 97 [34.6] 0.33  486 [34.8] 96 [34.4] -0.01 
       Prior Hypertension, n [%]  25818 [42.3] 208 [74.3] 0.66  1073 [76.9] 207 [74.2] -0.06 
       Prior Diabetes, n [%]  8536 [14.0] 113 [40.4] 0.61  531 [38.1] 112 [40.1] 0.04 
Case Mix, n [%]         
       Independent in ADLs prior to admission  47184 [77.2] 179 [63.9] <0.0001  1096 [78.6] 178 [63.8] <0.0001 
       Missing  5109 [8.4] 37 [13.2]   134 [9.6] 37 [13.3]  
       Living alone prior to admission  22065 [36.1] 64 [22.9] <0.0001  430 [30.8] 64 [22.9] 0.025 
       Missing  4453 [7.3] 36 [12.9]   124 [8.9] 36 [12.9]  
       Talking at first assessment  42795 [70.1] 196 [70.0] 0.386  1020 [73.1] 195 [69.9] 0.678 
       Missing  3707 [6.1] 26 [9.3]   93 [6.7] 26 [9.3]  
       Orientated at first assessment  35846 [58.7] 160 [57.1] 0.789  895 [64.2] 159 [57.0] 0.094 
       Missing  5325 [8.7] 35 [12.5]   128 [9.2] 35 [12.5]  
       Able to lift arms at first assessment  35622 [58.3] 178 [63.6] 0.013  833 [59.7] 178 [63.8] 0.092 
       Missing  4817 [7.9] 29 [10.4]   123 [8.8] 29 [10.4]  
       Able to walk on first assessment  23732 [38.9] 95 [33.9] 0.197  561 [40.2] 95 [34.1] 0.091 
       Missing  5529 [9.1] 34 [12.1]   141 [10.1] 34 [12.2]  
Index Stroke         
       Ischaemic   51606 [84.5] 255 [91.1]   1186 [85.0] 245 [91.0]  
       Haemorrhagic  6954 [11.4] 23 [8.2] 0.063  140 [10.0] 23 [8.2] 0.277 
       Missing  2527 [4.1] 2 [0.7]   69 [5.0] 2 [0.7]  
Admission Source         
       Acute Hospital  1984 [3.3] 22 [7.9] <0.001  31 [2.2] 21 [7.5] <0.0001 
       Sheltered/Care Home  2758 [4.5] 2 [0.7] <0.001  41 [2.9] 2 [0.7] 0.035 
       Home  54613 [89.4] 240 [85.7] 0.250  1277 [91.5] 240 [86.0] 0.050 
       Rehab/Other  904 [1.5] 7 [2.5] 0.133  31 [2.2] 7 [2.5] 0.661 
       Missing  828 [1.4] 9 [3.2]   15 [1.1] 9 [3.2]  
Management, n [%]         
       Admitted to Stroke unit  47619 [78.0] 189 [67.5] 0.002  1110 [79.6] 188 [67.4] <0.001 
       Missing  1415 [2.3] 16 [5.7]   24 [1.7] 16 [5.7]  
       Thrombolysis – IS only  2487 [4.8] 10 [3.9] 0.649  54 [4.6] 10 [3.9] 0.863 
       Missing  25009 [40.9] 126 [45]   560 [40.1] 125 [44.8]  
       Aspirin – IS only  43194 [83.7] 190 [74.5] <0.001  991 [83.6] 190 [74.8] 0.002 
       Missing  601 [1.0] 4 [1.4]   13 [0.9] 4 [1.4]  
       Swallow screen  48692 [79.7] 214 [76.4] 0.191  1098 [78.7] 213 [76.3] 0.433 
       Missing  2519 [4.1] 13 [4.6]   59 [4.2] 13 [4.7]  
       Brain Imaging  59680 [97.7] 278 [99.3] 0.257  1365 [97.9] 277 [99.3] 0.754 
       Missing  284 [0.5] 0   14 [1.0] 0  
Duration of Admission [IQR]  13 [37.0] 16 [38.0] 0.211  12 [33.0] 16 [38.0] 0.079 
Discharge Destination, n [%]         
       NHS Bed  3969 [6.5] 42 [15.0] <0.0001  66 [4.7] 42 [15.1] <0.0001 
       Care home  6390 [10.5] 15 [5.4] 0.003  100 [7.2] 15 [5.4] 0.302 
       Home/Sheltered  39125 [64.1] 153 [54.6] <0.001  979 [70.2] 152 [54.5] <0.0001 
       Other  782 [1.3] 4 [1.4] 0.786  25 [1.8] 4 [1.4] 0.806 
       Died  9694 [15.9] 62 [22.1] 0.007  188 [13.5] 62 [22.2] 0.001 
       Missing  1127 [1.8] 4 [1.4]   37 [2.7] 4 [1.4]  
Death at follow-up  33169 [54.3] 229 [81.8] <0.0001  676 [48.5] 228  [81.7] <0.0001 
 
Table 3 Demographics, presentation, management and outcomes following stroke form the Scottish Stroke Care Audit (SSCA) showing data before and after 
propensity score matching for all patient with end-stage renal disease. IQR, Interquartile Range; AF, Atrial Fibrillation; CeVD, Cerebrovascular Disease; IHD, 
Ischaemic Heart Disease; ADL, Activities of Daily Living ; IS, Ischaemic Stroke. † Standardized difference = difference in means or proportions divided by 
standard error; imbalance defined as absolute values greater than 0.20 
  
 Variable 
  
Non-ESRD 
Population 
(61,087) 
 
Dialysis Population 
(224) 
 
Standardised 
difference†/p-
value 
 
 
Propensity-Matched  
Non-ESRD Population 
(1115) 
 
Propensity-Matched 
Dialysis Population 
(223) 
 
Standardised 
difference†/p-
value 
 
Patient Demographics 
    
 
   
       Age at stroke, median years [IQR]  76 [17.0] 72 [16.0] -0.37  73 [15.0] 72 [16.0] -0.09 
       Female, n [%]  31368 [51.4] 119 [53.1] 0.04  613 [55.0] 118 [52.9] -0.04 
       Rural, n [%]  10015 [16.4] 35 [15.6] -0.02  169 [15.2] 35 [15.7] 0.01 
       Deprived, n [%]  29709 [48.6] 108 [48.2] -0.01  542 [48.6] 108 [48.4] 0.00 
       Prior AF, n [%]  5019 [8.2] 22 [9.8] 0.05  107 [9.6] 22 [9.9] 0.01 
       Prior CeVD, n [%]  3555 [5.8] 22 [9.8] 0.14  88 [7.9] 21 [9.4] 0.05 
       Prior IHD, n [%]  12025 [19.7] 82 [36.6] 0.37  435 [39.0] 81 [36.3] -0.06 
       Prior Hypertension, n [%]  25818 [42.3] 167 [74.6] 0.66  872 [78.2] 166 [74.4] -0.09 
       Prior Diabetes, n [%]  8536 [14.0] 93 [41.5] 0.63  445 [39.9] 92 [41.3] 0.03 
Case Mix, n [%]         
       Independent in ADLs prior to 
admission 
 
47184 [77.2] 138 [61.6] <0.0001 
 
886 [77.7] 137 [61.4] <0.0001 
       Missing  5109 [8.4] 28 [12.5]   118 [10.6] 28 [12.6]  
       Living alone prior to admission  22065 [36.1] 52 [23.2] <0.001  346 [31.0] 52 [23.3] 0.046 
       Missing  4453 [7.3] 27 [12.1]   95 [8.5] 27 [12.1]  
       Talking at first assessment  42795 [70.1] 159 [71.0] 0.377  797 [71.5] 158 [70.9] 0.856 
       Missing  3707 [6.1] 19 [8.5]   74 [6.6] 19 [8.5]  
       Orientated at first assessment  35846 [58.7] 13 [58.0] 0.824  686 [61.5] 129 [57.9] 0.508 
       Missing  5325 [8.7] 25 [11.2]   101 [9.1] 25 [11.2]  
       Able to lift arms at first assessment  35622 [58.3] 141 [63.0] 0.080  650 [58.3] 141 [63.2] 0.125 
       Missing  4817 [7.9] 21 [9.4]   99 [8.9] 21 [9.4]  
       Able to walk on first assessment  23732 [38.9] 69 [30.8] 0.026  420 [37.7] 69 [30.9] 0.068 
       Missing  5529 [9.1] 26 [11.6]   118 [10.6] 26 [11.7]  
Index Stroke         
       Ischaemic   51606 [84.5] 203 [90.6]   947 [84.9] 202 [90.6]  
       Haemorrhagic  6954 [11.4] 19 [8.5]   122 [10.9] 19 [8.5]  
       Missing  2527 [4.1] 2 [0.9] 0.145  46 [4.1] 2 [0.9] 0.239 
Admission Source         
       Acute Hospital  1984 [3.3] 22 [9.8] <0.0001  27 [2.4] 21 [9.4] <0.0001 
       Sheltered/Care Home  2758 [4.5] 2 [0.9] 0.005  30 [2.7] 2 [0.9] 0.147 
       Home  54613 [89.4] 186 [83.0] 0.019  1020 [91.5] 186 [83.4] 0.001 
       Rehab/Other  904 [1.5] 7 [3.1] 0.047  18 [1.6] 7 [3.1] 0.166 
       Missing  828 [1.4] 7 [3.1]   20 [1.8] 7 [3.1]  
Management, n [%]         
       Admitted to Stroke unit  49619 [78.0] 145 [64.7] <0.001  888 [79.6] 144 [64.6] <0.001 
       Missing  1415 [2.3] 16 [7.1]   27 [2.4] 16 [7.2]  
       Thrombolysis – IS only  2487 [4.8] 7 [3.5] 0.496  47 [5.0] 7 [3.5] 0.568 
       Missing  25009 [40.9] 100 [44.6]   439 [39.4] 99 [44.4]  
       Aspirin – IS only  43194 [83.7] 152 [74.9] 0.002  788 [83.2] 152 [75.3] 0.010 
       Missing  601 [1.0] 3 [1.3]   11 [1.0] 3 [1.3]  
       Swallow screen  48692 [79.7] 173 [77.2] 0.315  903 [81.0] 172 [77.1] 0.229 
       Missing  2519 [4.1] 9 [4.0]   38 [3.4] 9 [4.0]  
       Brain Imaging  59680 [97.7] 222 [99.1] 0.450  1095 [98.2] 221 [99.1] 1.000 
       Missing  284 [0.5] 0   6 [0.5] 0  
Duration of Admission [IQR]  13 [37.0] 17 [39.0] 0.101  12 [36.0] 17 [39.0] 0.027 
Discharge Destination, n [%]         
       NHS Bed  3969 [6.5] 38 [17.0] <0.0001  53 [4.8] 38 [17.0] <0.0001 
       Care home  6390 [10.5] 14 [6.3] 0.037  97 [8.7] 14 [6.3] 0.287 
       Home/Sheltered  39125 [64.1] 114 [50. 9] <0.0001  765 [68.6] 113 [50.7] <0.0001 
       Other  782 [1.3] 4 [1.8] 0.541  19 [1.7] 4 [1.8] 1.000 
       Died  9694 [15.9] 51 [22.7] 0.008  160 [14.4] 51 [22.9] 0.002 
       Missing  1127 [1.8] 3 [1.3]   21 [1.9] 3 [1.3]  
Death at end follow – up  33169 [54.3] 192 [85.7] <0.0001  590 [52.9] 191 [85.7] <0.0001 
 
Table 4 Demographics, presentation, management and outcomes following stroke form the Scottish Stroke Care Audit (SSCA) showing data before and after 
propensity score matching for people on dialysis for end-stage renal disease. IQR, Interquartile Range; AF, Atrial Fibrillation; CeVD, Cerebrovascular 
Disease; IHD, Ischaemic Heart Disease; ADL, Activities of Daily Living ; IS, Ischaemic Stroke. † Standardized difference = difference in means or proportions 
divided by standard error; imbalance defined as absolute values greater than 0.20 
 
  
 Variable 
  
Non-ESRD Population 
(61,087) 
 
Kidney  Transplant 
(RT) Population 
(56) 
 
Standardised 
difference†/p-
value 
 
 
Propensity-Matched Non-
ESRD Population (280) 
 
Propensity-Matched 
RT Population (56) 
 
Standardised 
difference†/p-
value 
 
Patient Demographics 
    
 
   
       Age, median years [IQR]  76 [17.0] 65.5 [15.0] -0.99  66 [15] 65.5 [15.0] -0.12 
       Female, n [%]  31368 [51.4] 21 [37.5] -0.28  101 [36.1] 21 [37.5] 0.03 
       Rural, n [%]  10015 [16.4] 6 [10.7] -0.17  22 [7.9] 6 [10.7] 0.10 
       Deprived, n [%]  29709 [48.6] 30 [53.6] 0.10  156 [55.7] 30 [53.6] -0.04 
       Prior AF, n [%]  5019 [8.2] 4 [7.1] -0.05  12 [4.3] 4 [7.1] 0.12 
       Prior CeVD, n [%]  3555 [5.8] 5 [8.9] 0.11  27 [9.6] 5 [8.9] -0.02 
       Prior IHD, n [%]  12025 [19.7] 15 [26.8] 0.15  79 [28.2] 15 [26.8] -0.03 
       Prior Hypertension, n [%]  25818 [42.3] 41 [73.2] 0.63  207 [73.9] 41 [73.2] -0.02 
       Prior Diabetes, n [%]  8536 [14.0] 20 [35.7] 0.51  101 [36.1] 20 [35.7] -0.01 
Case Mix, n [%]         
       Independent in ADLs prior to admission  47184 [77.2] 41 [73.2] 0.692  236 [84.3] 41 [73.2] 0.597 
       Missing  5109 [8.4] 9 [16.1]   19 [6.8] 9 [16.1]  
       Living alone prior to admission  22065 [36.1] 12 [21.4] 0.072  85 [30.4] 12 [21.4] 0.397 
       Missing  4453 [7.3] 9 [16.1]   18 [6.4] 9 [16.1]  
       Talking at first assessment  42795 [70.1] 37 [66.1] 1.000  218 [77.9] 37 [66.1] 0.322 
       Missing  3707 [6.1] 7 [12.5]   14 [5.0] 7 [12.5]  
       Orientated at first assessment  35846 [58.7] 30 [53.6] 1.000  194 [69.3] 30 [53.6] 0.214 
       Missing  5325 [8.7] 10 [17.9]   18 [6.4] 10 [17.9]  
       Able to lift arms at first assessment  35622 [58.3] 37 [66.1] 0.052  187 [66.8] 37 [66.1] 0.486 
       Missing  4817 [7.9] 8 [14.3]   18 [6.4] 8 [14.3]  
       Able to walk on first assessment  23732 [38.9] 26 [46.4] 0.111  128 [45.7] 26 [46.4] 0.638 
       Missing  5529 [9.1] 8 [14.3]   21 [7.5] 8 [14.3]  
Index Stroke         
       Ischaemic   51606 [84.5] 52 [92.9]   242 [86.4] 52 [92.9]  
       Haemorrhagic  6954 [11.4] 4 [7.1]   30 [10.7] 4 [7.1]  
       Missing  2527 [4.1] 0 0.405  8 [2.9] 0 0.477 
Admission Source         
       Acute Hospital  1984 [3.3] 0 0.426  11 [3.9] 0 0.223 
       Sheltered/Care Home  2758 [4.5] 0 0.180  8 [2.9] 0 0.362 
       Home  54613 [89.4] 54 [96.4] 0.009  255 [91.1] 54 [96.4] 0.032 
       Rehab/Other  904 [1.5] 0 1.000  2 [0.7] 0 1.000 
       Missing  828 [1.4] 2 [3.6]   4 [1.4] 2 [3.6]  
Management, n [%]         
       Admitted to Stroke unit  47619 [78.0] 44 [78.6] 0.868  221 [78.9] 44 [78.6] 0.712 
       Missing  1415 [2.3] 0   7 [2.5] 0   
       Thrombolysis – IS only  2487 [4.8] 3 [5.8] 0.731  8 [3.3] 3 [5.8] 0.407 
       Missing  25009 [40.9] 26 [46.4]   119 [42.5] 26 [46.4]  
       Aspirin – IS only  43194 [83.7] 38 [73.1] 0.051  200 [82.6] 38 [73.1] 0.157 
       Missing  601 [1.0] 1 [1.8]   3 [1.1] 1 [1.8]  
       Swallow screen  48692 [79.7] 41 [73.2] 0.457  222 [79.3] 41 [73.2] 0.565 
       Missing  2519 [4.1] 4 [7.1]   9 [3.2] 4 [7.1]  
       Brain Imaging  59680 [97.7] 56 [100.0] 0.629  276 [98.6] 56 [100] 1.000 
       Missing  284 [0.5] 0   4 [1.4] 0  
Duration of Admission [IQR]  13 [37] 11 [32] 0.683  11 [22] 11 [32] 0.541 
Discharge Destination, n [%]         
       NHS Bed  3969 [6.5] 4 [7.1] 0.784  16 [5.7] 4 [7.1] 0.756 
       Care home  6390 [10.5] 1 [1.8] 0.027  15 [5.4] 1 [1.8] 0.488 
       Home/Sheltered  39125 [64.1] 39 [69.6] 0.479  214 [76.4] 39 [69.6] 0.292 
       Other  782 [1.3] 0 1.000  3 [1.1] 0 1.000 
       Died  9694 [15.9] 11 [19.6] 0.462  26 [9.3] 11 [19.6] 0.034 
       Missing  1127 [1.8] 1 [1.8]   6 [2.1] 1 [1.8]  
Death at follow-up  33169 [54.3] 37 [66.1] 0.082  117 [41.8] 37 [66.1] 0.001 
 
Table 5 Demographics, presentation, management and outcomes following stroke form the Scottish Stroke Care Audit (SSCA) showing data before and after 
propensity score matching for people with a renal transplant. IQR, Interquartile Range; AF, Atrial Fibrillation; CeVD, Cerebrovascular Disease; IHD, Ischaemic 
Heart Disease; ADL, Activities of Daily Living ; IS, Ischaemic Stroke. † Standardized difference = difference in means or proportions divided by standard error; 
imbalance defined as absolute values greater than 0.20 
 
 
Alive Dead p-value 
n 4136 4621 
 Age at first RRT, median years (IQR) 44.6 (27.0) 67 (20.8) <0.0001 
Sex, n (%)       
       Female 1743 (42.1) 1932 (41.8) 
        Male 2393 (57.9) 2689 (58.2) 0.761 
Primary Renal Diagnosis Group (%)       
       Missing 1 (0.02) 11 (0.2) 
        Glomuleronephritis 989 (23.9) 613 (13.3) <0.0001 
       Interstitial disease 1403 (33.9) 904 (19.6) <0.0001 
       Multisystem 613 (14.8) 1181 (25.6) <0.0001 
       Diabetic nephropathy 540 (13.1) 1045 (22.6) <0.0001 
       Other 590 (14.3) 867 (18.8) <0.0001 
Urban-Rural (%)       
       Rural 722 (17.5) 733 (15.9) 
        Urban 3414 (82.5) 3888 (84.1) 0.047 
SIMD (%)       
       Least Deprived  3080 (74.5) 3405 (73.7) 
        Most Deprived  1056 (25.5) 1216 (26.3) 0.407 
Past Medical History (%)       
       Atrial Fibrillation  76 (1.8) 478 (10.3) <0.0001 
       Ischaemic Heart disease 743 (18.0) 1952 (42.2) <0.0001 
       Stroke 60 (1.5) 260 (5.6) <0.0001 
       Diabetes 935 (22.6) 1726 (37.4) <0.0001 
       Hypercholesterolaemia  423 (10.2) 710 (15.4) <0.0001 
       Obesity  201 (4.9) 294 (6.4) 0.004 
       HBP  2887 (69.8) 3368 (72.9) 0.017 
Clinical Variables. Median (IQR)       
       Systolic BP, mmHg 138.0 (27.0) 138.5 (31.5) 0.755 
       Diastolic BP, mmHg 75.0 (17.0) 69.0 (19.0) <0.0001 
       Weight, kg  75.2 (23.0) 70.3 (22.3) <0.0001 
Laboratory Variables       
       Haemoglobin, g/L 12 (2.0) 11.3 (1.8) <0.0001 
       Albumin, mmol/L 39 (6.0) 36 (7.0) <0.0001 
       Serum Phosphate, mmol/L 1.21 (0.6) 1.45 (0.6) <0.0001 
       Adjusted Calcium, mmol/L 2.38 (0.2) 2.36 (0.2) <0.0001 
       ESA Use 
   Stroke during study period (%) 53 (1.3) 433 (9.4) <0.0001 
 
Table 6 Baseline demographics of all end-stage renal disease patients, alive vs dead at end of follow-
up. IQR, Interquartile Range; SIMD, Scottish Index of Multiple Deprivation; RRT, Renal Replacement 
Therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; ESA, erythropoietin-stimulating 
agent.  
 



